Interstitial lung disease associated with gefitinib
Interstitial lung disease associated with gefitinib
复制标题
DOI：
10.1016/j.rmed.2005.07.015
复制
发表时间：
2006-04-01
影响因子：
4.3
通讯作者：
Shimokata, K
中科院分区：
文献类型：
--
作者：
Kataoka, K;Taniguchi, H;Shimokata, K
尽管最近报道了与吉非替尼（一种表皮生长因子受体抑制剂）相关的肺毒性，但临床信息的积累和吉非替尼诱导的间质性肺疾病（ILD）的潜在机制仍然不足和不清楚。在回顾性回顾489例接受吉非替尼治疗的肺癌患者的临床记录和胸部x光片后，我们诊断出4例吉非替尼诱导的ILD，他们接受了纤维支气管镜检查和支气管肺泡灌洗（BAL）。我们发现，从开始使用吉非替尼到ILD发作的时间很短，并得出结论，建议仔细和密切观察胸部影像学研究和呼吸道症状的集合。所有4例患者均接受高剂量皮质类固醇治疗，ILD得到解决。我们在BAL液中检测到高水平的干扰素诱导蛋白-10，尽管我们不能证明实验室结果或BAL液细胞分析的特征。我们推测Th1型肺组织炎症或肺损伤可能参与吉非替尼诱导ILD的部分机制。(c) 2005 Elsevier Ltd版权所有。
Although pulmonary toxicity associated with gefitinib, an epidermal growth factor receptor inhibitor, has been reported recently, the accumulation of clinical information and the underlying mechanisms of gefitinib-induced interstitial lung disease (ILD) remain insufficient and unclear. After retrospectively reviewing the clinical records and chest X-rays of 489 lung cancer patients who were treated with gefitinib, we diagnosed four cases of gefitinib-induced ILD who underwent fiberoptic bronchoscopy and bronchoalveolar lavage (BAL). We found that the period of time from starting gefitinib to the onset of ILD was short, and concluded that a careful and close observation of a chest imaging study and a collection of respiratory symptoms was recommended. All four patients were treated with a high dose of corticosteroids, and ILD was resolved. We detected high levels of interferon-inducible protein-10 in BAL fluid, although we could not demonstrate the characteristic features of laboratory findings or BAL fluid cell analysis. We speculated that a Th1 type of lung tissue inflammation or lung injury might be involved as a part of mechanisms underlying gefitinib-induced ILD. (c) 2005 Elsevier Ltd. All rights reserved.